A. George

发表

Prognostic impact of monocyte count at presentation in mantle cell lymphoma

J. Szer, H. Prince, J. Seymour, 2013, British journal of haematology.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2019, The Lancet. Haematology.

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

I. Lewis, P. Marlton, H. Prince, 2018, Leukemia & lymphoma.

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.

E. Giné, D. Šálek, H. Kluin-Nelemans, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

M. Dimopoulos, K. Konstantopoulos, M. Mohty, 2021, The Lancet.

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma

S. Lade, R. Hicks, M. Hofman, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1

R. Glasspool, I. McNeish, U. Banerji, 2022, medRxiv.

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

C. Tam, H. Prince, S. Harrison, 2014, Annals of Hematology.

Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era.

C. Tam, J. Seymour, A. Herschtal, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.

J. Connors, K. Savage, T. Panzarella, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

S. Opat, C. Tam, H. Prince, 2014, British Journal of Cancer.

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

C. Tam, J. Seymour, A. George, 2013, Leukemia & lymphoma.

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

R. Hájek, P. Moreau, Kihyun Kim, 2020, Blood advances.

A different kind of “allogeneic transplant”: successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma

Jennifer S. Barnett, H. Prince, A. Heriot, 2015, Leukemia & lymphoma.

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

S. Opat, C. Tam, H. Prince, 2013 .

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2018 .